Philogen S.p.A.

Milan Stock Exchange PHIL.MI

Philogen S.p.A. Operating Income Margin for the year ending December 31, 2023: -38.22%

Philogen S.p.A. Operating Income Margin is -38.22% for the year ending December 31, 2023, a -3,876.17% change year over year. Operating Income Ratio is the proportion of a company's operating income to its net sales, measuring the efficiency of its core business operations in generating profits.
  • Philogen S.p.A. Operating Income Margin for the year ending December 31, 2022 was 1.01%, a 100.15% change year over year.
  • Philogen S.p.A. Operating Income Margin for the year ending December 31, 2021 was -672.08%, a -164.75% change year over year.
  • Philogen S.p.A. Operating Income Margin for the year ending December 31, 2020 was -253.85%, a -632.57% change year over year.
  • Philogen S.p.A. Operating Income Margin for the year ending December 31, 2019 was -34.65%, a -1,046.82% change year over year.
Key data
Date Operating Income Margin EBT Margin Net Income Margin EBITDA Margin
Market news
SV Wall Street
Milan Stock Exchange: PHIL.MI

Philogen S.p.A.

CEO Prof. Dario Neri Ph.D.
IPO Date March 3, 2021
Location Italy
Headquarters Via Bellaria, 35
Employees 174
Sector Healthcare
Industries
Biotechnology Clinical Trials Pharmaceuticals Vaccines
Description

Philogen S.p.A., a biotechnology company, develops drugs for oncology and chronic inflammatory diseases. It is developing Nidlegy, a combination of the immunocytokines L19IL2 and L19TNF developed intralesional treatment for locoregional melanoma and non-melanoma skin cancers; Fibromun, a human immunomodulatory product consisting of L19 antibody and TNF to treat soft tissue sarcoma, leiomyosarcoma, and glioma; and Darleukin (L19IL2), a human immunostimulatory product consisting of the human L19 antibody fused to the human cytokine interleukin-2 (IL2), which is in phase II clinical trial for the treatment of non-small cell lung cancer. The company is also developing Dodekin, a human immunostimulatory product that comprises vascular targeting antibody fused to interleukin-12 that is in phase I/II clinical trial to treat advanced solid tumors; Dekavil (F8IL10), an anti-inflammatory product, which is in phase I clinical trial for the treatment of chronic inflammation; Onco IX (PHC-102), a 99mTc labelled small molecule radiotracer for the non-invasive detection of carbonic anhydrase IX (CAIX) expressing solid tumors that is in phase 1 clinical trial; and OncoFAP, a small molecule radiotracer for the non-invasive detection of various metastatic solid tumors targeting fibroblast activation protein, which is in phase 1 clinical trial. Philogen S.p.A. was founded in 1996 and is based in Sovicille, Italy.

StockViz Staff

February 7, 2025

Any question? Send us an email